Detail akcie Mode online

Business Summary: Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Sygnis SA revenues decreased 33% to PLN15.7M. Net loss applicable to common stockholders increased from PLN2.2M to PLN8.2M. Revenues reflect Sales of Goods and Materials decrease of 31% to PLN12.5M, Sales of Products decrease of 41% to PLN3.2M. Higher net loss reflects Grants decrease of 88% to PLN212K (income), Salaries increase of 15% to PLN7.5M (expense).